10-K: Arbutus Biopharma Outlines Capital Structure and Pipeline Progress in Annual 10-K Filing

Arbutus Biopharma's annual 10-K filing details its capital structure, ongoing clinical trials, and strategic focus on developing a functional cure for chronic hepatitis B.

Summary

• Arbutus Biopharma is a clinical-stage company focused on developing a functional cure for chronic hepatitis B (cHBV).
• The company's pipeline includes imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor.
• As of March 1, 2024, Arbutus had 179,492,199 common shares outstanding and no Series A preferred shares.
• Arbutus anticipates a net cash burn between $63.0 million and $67.0 million in 2024, excluding proceeds from its Open Market Sale Agreement with Jefferies.
• The company believes it has sufficient cash resources to fund operations into the first quarter of 2026.
• Arbutus is conducting Phase 2a clinical trials combining imdusiran with Peg-IFN-2a and Barinthus VTP-300, and plans to initiate another Phase 2a trial with durvalumab in the first half of 2024.
• The company is also advancing AB-101 in a Phase 1a/1b clinical trial in New Zealand after receiving a clinical hold from the FDA in the US.
• Arbutus has a licensing agreement with Qilu Pharmaceutical for imdusiran in China, Hong Kong, Macau, and Taiwan, which includes a $40 million upfront payment and potential milestone payments up to $245 million.
• The company also has royalty entitlements from Alnylam's ONPATTRO sales, with a portion of the royalties sold to OMERS, and a second royalty interest from Acuitas.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical trials and strategic partnerships, the company faces significant challenges, including a clinical hold, financial losses, and competition. The sentiment is neutral to slightly negative due to the challenges and risks outlined.

Positives

• Imdusiran has demonstrated significant reductions in HBsAg and HBV DNA, supporting its potential as a cornerstone therapy.
• The company has multiple ongoing Phase 2a clinical trials evaluating imdusiran in combination with other agents.
• Arbutus has a strategic partnership with Qilu Pharmaceutical for the development and commercialization of imdusiran in a key market.
• The company has a royalty stream from Alnylam's ONPATTRO sales, which could provide future revenue.
• Arbutus has sufficient cash resources to fund operations into the first quarter of 2026.

Negatives

• The FDA has placed a clinical hold on the IND application for AB-101, requiring the company to pursue other regulatory pathways.
• The company has incurred losses in nearly every year since its inception and does not expect to achieve profits for the foreseeable future.
• The company is dependent on third parties for manufacturing and clinical trials, which exposes it to risks.
• The company faces significant competition from other biotechnology and pharmaceutical companies targeting HBV.
• The company is subject to ongoing regulatory requirements and oversight, which could lead to delays or restrictions.

Risks

• The company is in the early stages of development, and there is limited information about its product candidates.
• Arbutus will require substantial additional capital to fund its operations, which may be dilutive to shareholders.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, with uncertain outcomes.
• Preclinical and preliminary data may not be predictive of later clinical trial results.
• The company may face difficulties enrolling patients in clinical trials.
• The FDA may not accept data from trials conducted outside the United States.
• The company may not obtain regulatory approval for its product candidates.
• The company may face product liability lawsuits.
• Coverage and adequate reimbursement may not be available for its product candidates.
• The company is subject to healthcare laws and regulations, which could expose it to penalties.
• The company depends on third parties for manufacturing and clinical trials, which exposes it to risks.
• The company's patents may be challenged and found to be invalid.
• The company may incur substantial costs as a result of litigation relating to intellectual property rights.
• The company may be deemed a passive foreign investment company, which could have adverse tax consequences for investors.
• The company's articles and certain Canadian laws could delay or deter a change of control.

Future Outlook

Arbutus believes it has sufficient cash resources to fund operations into the first quarter of 2026 and plans to initiate a Phase 2a clinical trial with durvalumab in the first half of 2024.

Management Comments

• The company is focused on developing a functional cure for chronic hepatitis B.
• Arbutus is positioning imdusiran as a potential cornerstone therapeutic in combination with other agents.
• The company is advancing AB-101 in a Phase 1a/1b clinical trial in New Zealand.

Industry Context

The document highlights the competitive landscape in the HBV treatment market, with several companies developing various therapeutic approaches. Arbutus is positioning itself with a combination therapy approach, which is a growing trend in the industry.

Comparison to Industry Standards

• Arbutus's approach to combining RNAi therapeutics with immune modulators aligns with the industry's focus on multi-pronged strategies for HBV.
• The company's clinical trial designs, such as the combination of imdusiran with Peg-IFN-2a and VTP-300, are comparable to other companies exploring combination therapies.
• The company's financial position, with cash runway into the first quarter of 2026, is similar to other clinical-stage biotech companies.
• The company's reliance on third-party manufacturers and CROs is a common practice in the biotech industry.
• The company's patent litigation with Moderna and Pfizer/BioNTech is a common occurrence in the biotech industry, where intellectual property is highly valuable.

Management Changes

Corporate Governance

Legal Proceedings

• Arbutus and Genevant filed a lawsuit against Moderna for patent infringement related to the COVID-19 vaccine.
• Arbutus and Genevant filed a lawsuit against Pfizer and BioNTech for patent infringement related to COVID-19 mRNA-LNP vaccines.
• Acuitas filed a lawsuit against Arbutus and Genevant seeking a declaratory judgment that Arbutus patents do not infringe Pfizer and BioNTech's COVID-19 vaccine.
• Moderna filed a petition requesting the United States Patent and Trademark Office to institute an Inter Partes Review of Arbutus United States Patent 9,404,127.
• Moderna and Merck filed Notices of Opposition to Arbutus European patent EP 2279254 with the European Patent Office.

Related Party Transactions

• The company has a licensing agreement with Qilu Pharmaceutical, an affiliate of which purchased 3,579,952 of the company's common shares at a premium.
• The company has a relationship with Roivant Sciences Ltd., its largest shareholder, through the launch of Genevant Sciences Ltd.

Stakeholder Impact

• Shareholders may experience dilution due to potential equity financings.
• Employees may be affected by changes in compensation and benefits.
• Patients may benefit from the development of new treatments for HBV.
• Suppliers and partners may be affected by changes in the company's strategy and operations.
• Creditors may be affected by the company's financial performance and ability to repay debts.

Next Steps

• Initiate a Phase 2a clinical trial evaluating imdusiran in combination with durvalumab in the first half of 2024.
• Advance AB-101 in a Phase 1a/1b clinical trial in New Zealand.
• Continue to evaluate imdusiran in Phase 2a proof-of-concept combination clinical trials.
• Seek additional funding to maintain and advance the business.

Key Dates

Keywords

Hepatitis B, HBV, Imdusiran, AB-729, AB-101, RNAi, PD-L1 inhibitor, Clinical trials, Functional cure, Biopharmaceutical, LNP, ONPATTRO, Qilu Pharmaceutical, Alnylam, Genevant, Intellectual property, Regulatory approval